Claritas Pharmaceuticals Inc. buy melinda
Start price
22.06.17
/
50%
€2.16
Target price
16.11.17
€4.04
Performance (%)
-16.54%
End price
16.11.17
€1.80
Summary
This prediction ended on 16.11.17 with a price of €1.80. The prediction for Claritas Pharmaceuticals Inc. disappointed with a performance of -16.54%. melinda has 50% into this predictionPerformance without dividends (%)
Name | 1w | 1m | 1y | 3y |
---|---|---|---|---|
Claritas Pharmaceuticals Inc. | - | - | - | - |
iShares Core DAX® | 2.687% | -4.620% | 11.789% | 9.959% |
iShares Nasdaq 100 | 5.569% | -7.315% | 24.297% | 36.179% |
iShares Nikkei 225® | 3.756% | -7.813% | 10.017% | 3.466% |
iShares S&P 500 | 3.959% | -3.697% | 21.637% | 35.681% |
Comments by melinda for this prediction
In the thread Claritas Pharmaceuticals Inc. diskutieren
zu folgen
22. Juni (Reuters) - Kalytera Therapeutics Inc. :: Kalytera Therapeutics Inc. - Robert Farrell, JD, Präsident und CFO von Kalytera, wird die Rolle des Interim Chief Executive Officer übernehmen. Kalytera Therapeutics - erwartet für Patienten in einer klinischen Phase-2-Studie zur Beurteilung cbd beginnen Einschreibung ...
(Vom Mitglied beendet)
Stopped prediction by melinda for Claritas Pharmaceuticals Inc.
Claritas Pharmaceuticals Inc.
Start price
Target price
Perf. (%)
€2.16
22.06.17
22.06.17
€4.04
16.11.17
16.11.17
-16.54%
16.11.17
16.11.17